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Abstract 
We have investigated the C-terminal tail of the rat substance P receptor (SPR) as a domain essential for agonist-induced esensitization. Four 
progressively shorter mutants, using premature termination in the C-terminus, were constructed and compared with the unaltered SPR using ectopic 
expression of wild-type and mutant receptors in Xenopus oocytes. These mutants were designated D16, D47, D70 and D96 with 16,47,70 and 96 
amino acids residues deleted from the tail, respectively. Wild type SPR, D16 and D47 exhibited normal current responses when challenged with 
substance P, but D70 and D96 had reduced maximal current responses (70% and 5% of wild type SPR, respectively). D70, however, exhibited 
substantial resistance to substance P-induced desensitization i  that 55%, versus 8% for wild type SPR, of the peak current of the 6rst response was 
preserved on second challenge with substance P. Therefore, a domain from residues 338 to 360 of the rat SPR, though not necessary for the functional 
activity of the receptor, plays an essential role in agonist-induced esensitization. 
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1. Intruduetion 
Substance P receptor (SPR) is a widely distributed 
neuropeptide receptor in nervous and peripheral tissues, 
and plays roles in a number of biological processes [1,2]. 
Molecular cloning has revealed that SPR is a member of 
the superfamily of G protein-coupled seven transmem- 
brane receptors [3,4]. Functional analysis of the cloned 
receptor in heterologous cells has confirmed that activa- 
tion of the receptor leads to intracellular calcium mobili- 
zation, which can be conveniently monitored in Xenopus 
oocytes by current responses under voltage clamp [3]. 
Although the SPR shows rapid and long-lived desensiti- 
zation in response to repeated application of substance 
P (SP) when expressed in Xenopus oocytes, the mecha- 
nisms of desensitization remain to be clarified [2]. Re- 
cently, the SPR has been shown to be multiply 
phosphorylated in vitro by the regulatory enzymes, 
j?-adrenergic receptor kinase (BARK) 1 and 2 , only in 
the presence of agonist [5]. This suggests that the agonist- 
dependent regulation of SPR may be mediated in part 
through /3ARK enzymes, which are known to phospho- 
rylate &adrenergic receptors at the C-terminal tail [6]. 
We have investigated the predicted importance of the 
C-terminus for agonist-induced esensitization using ec- 
topic expression of SPR and truncated mutants in Xen- 
opus oocytes. 
2. Materials and methods 
2.1. SPR and SPR mutant expression vectors 
The coding regions for the SPR was amplised by polymerase chain 
reaction @‘CR) using rat SPR cDNA (prTKR2 ; [3]). The amplified 
SPR was subcloned into the pRc/CMV vector (Invitrogen, San Diego, 
CA) which allowed readily detectable receptor expression in Xenopus 
oocytes. PCR reactions were as follows: 100 ng of SPR cDNA plasmid 
was used in 30 PCR cycles in the presence of 200 mM each of the dNTP, 
1.5 mM of MgC&, 2.5 Units of AmpliTaq DNA polymerase (Perkin- 
Elmer, Norwalk, CT) and using two receptor-specific primers. Each 
cycle involved a denaturation step (95”C, 1 min), an annealing step 
(49”C, 1.5 min) and a extension step (72”C, 1.5 min). The upstream 
primers contained a Hind111 restriction site, a translational consensus 
sequence, and the receptor specific sequence. The down stream primers 
contained an XbaI restriction site, a translation termination codon and 
the receptor spedc sequence as indicated: SPR-FuU (SPR 5-END = 
5’-ACTC Ap;GCTT dGCCACC ATGGATAACG’i’CCTTCCTAT- 
GGACJ’, and SPR 3-F = 5/-T-l-l-f GAA-ITC TCTAGA CTAGGC- 
CAGCATGTT AGAGTA3’) (underlined nucleotides are receptor- 
specific). A similar PCR procedure was used to generate tail truncation 
mutants in rat SPR. Lehgth of tail deletion was selected to include 
clusters of serine and threonine residues; possible phosphorylation sites. 
In addition to the full length SPR (designated Full), we made deletions 
D16, D47, D70 and D96 (the number represents amino acids residues 
deleted from the C-terminal end of the receptor, see Fig. 1). Substance 
P receptor downstream PCR deletion primers were: 1. D16 = (SPR 
3-D 16 5’-m TCTAGA CTAGTTWGCGAGAGGAGCC-3’). 
2. D47 (SPR 3-D47 = 5’--l-l-IT TCTAGA CTAAGTGGAG ATGG- 
TGGTCTC3’). 3. D70 = (SPR 3-D70 = 5’--l-I-IT TCTAGA CTAT- 
TTCATTTCCAGCCCCTC-3’). 4, D96 (SPR 3-D96 = 5’-T-l-IT TCT- 
AGA CTACCTGTCG TTGAGGCAACA3’). The amplified receptor 
DNA fragments were purified and concentrated using Amicon columns 
(Amicon, Beverly, MA), restricted with Hind111 and XbaI and cloned 
into the pRc/CMV plasmid using the unique ZfindII-XbaI sites. Two 
different plasmid constructs were generated and analyzed in the Xen- 
opus oocytes for Full SPR and for each of the mutants to confirm the 
results obtained. 
*Corresponding author. Fax: (1) (916) 752 3516. 
Abbreviations: SPR, substance P receptor; SP, substance P; BARK, 
/I-adrenergic receptor kinase; SEAP, secreted alkaline phosphatase. 
2.2. Preparation of oocytes 
Xenopus laevis were injected with pregnant mares serum (50 IU) 
2448 h before ovarectomy. The ovaries were washed with OR-2 solu- 
tion: 82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl,, 1.0 mM CaCl,, 
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2.5 mM NaHC03 and 5 mM HEPES (PH 7.4). Oocytes were isolated 
by treating the ovaries with collagenase type I (2 mg/ml) made in 
Ca*‘-free OR-2 solution for 10~110 min. Stage VI oocytes were se- 
lected and rolled on plastic culture dishes to insure complete removal 
of the follicle cells [a. The defolliculated oocytes were cultured for 
16-18 h at 18°C in Moditied Barths solution: 88 mM NaCI. 1.0 mM 
KCl, 0.82 mM MgSO,, 0.41 mM CaCl,, 0.33 mM Ca(N0&,‘2.42 mM 
NaHCOS, 10 mM HEPES, 3OO,&nl Na-pyruvate, lo&ml penicillin, 
IO&ml streptomycin, lo&ml gentamycin and 0.5% chicken ovalbu- 
min (pH 7.6). 
2.3. Microinjection of SPR expression vector 
The oocytes were placed on a bed of 35% of Ficoll with OR2 solution 
in 50 ml plastic conical tubes and centrifuged 750 x g for 10 min. This 
makes the nucleus visible as a white spot. The oocytes were transferred 
to an injection dish which has a layer nylon meshes (grid size, 1.5 mm) 
in the bottom in order to hold the oocytes. The oocytes were microin- 
jetted by pressure using a picospritzer (General Valve Corp, Fairfield, 
NJ). The amount injected was determined by injecting a droplet in the 
air and measuring the volume of the droplet. A 5 nl of plasmid in TE 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) was injected into the 
nucleus. In order to confirm that the nucleus has been successfully 
microinjected, pMT2-secreted alkaline phosphatase (SEAP) plasmid 
(100 pg/oocyte) was coinjected with SPR (100 pg/oocyte) as described 
previously [8,9]. The oocytes were cultured 4-5 h in Modified Barths 
solution at 18°C. The oocytes were then transferred individually to 
96-well plates containing 200 ~1 of Modified Barths solution and cul- 
tured for 48 h. SEAP activity in the media was assayed calorimetrically 
as previously described [8,9]. 
2.4. Electrophysiology 
SEAP expressing oocytes were selected and were voltage-clamped at 
-60 mV with a two-electrode voltage clamp (Dagan Model TEV-200, 
Minneapolis, MN) [7l. The oocytes were continually perfused (flow 
rate: 3.4-3.6 ml/mm) with OR-2 solution in chamber. Stimulant (SP 
solution) was applied to the cell chamber from another reservoir. The 
oocytes were exposed to stimulant for 18 s. The electrophysiology 
experiments were performed at 23-26 “C. The results were collected 
with Axotape software (Axon Instruments, Foster City, CA) and were 
plotted with Axoplot software. 
2.5. Materials 
Materials were obtained from: SP peptide from Peninsula laborato- 
ties (Belmont, CA); the pRc/CMV plasmid from Invitrogen, (San 
Diego. CA). the cDNA clone for rat SPR (nrTKR2) was a gift from 
Dr.-Shigemda Nakanishi (Kyoto universi& Kyoto, Japan); pMT2 
plasmid containing SEAP cDNA was kindly provided by the Genetics 
Institute (Cambridge, MA). 
3. Results and discussion 
The predicted intracellular C-terminus has the greatest 
sequence divergence between the three closely related 
tachykinin receptors [2]. In addition, naturally occurring 
C-terminal truncations of transcripts [lo] or SPR protein 
[l l] have been reported, suggesting alternative transcrip- 
tion may produce a variant SPR lacking a significant 
intracellular tail. These observations imply a physiologi- 
cal importance for this region. Truncation mutations in 
the C-terminal tail were constructed based on the cluster- 
ing of serine/threonine amino acid residues. Our ration- 
ale was that the SPR was shown to be phosphorylated 
in vitro by the G-protein coupled receptor kinases; 
/IARK 1 and 2 [5] suggesting phosphorylation of serinel 
threonine residues, localized to the C-terminal tail in the 
case of the /3,-adrenergic receptor [6], may play a role in 
agonist-induced esensitization. Accordingly, four dif- 
Fig. 1. A schematic presentation of the predicted structure of rat SP 
receptor showing the exact amino acid residues of the C-terminal tail. 
The wild type of SPR (Full) and the positions of the constructed trun- 
cation mutants (Dl6, D47, D70 and D96) are indicated. The designa- 
tion of each mutant represents the number of residues deleted from the 
C-terminal. The numbers (312, 338 and 360) refer to amino acid posi- 
tions. 
ferent truncation mutants in the tail of SPR were con- 
structed; designated ‘D16’, ‘D47’, ‘D70’ and ‘D96’ with 
16, 47, 70 and 96 amino acids residues deleted from the 
tail, respectively (Fig. 1). Their functional activities and 
sensitivity to agonist-induced esensitization were com- 
pared with the unaltered SPR (‘Full’). The D96 corre- 
sponded to the naturally truncated, potentially alter- 
natively spliced variant, described earlier [lo]. The 
functional expression of SPR and mutants was examined 
by voltage-clamp analysis of SP-induced currents. 
Fig. 2 (left panels, ‘First’) shows typical first applica- 
tion of SP-induced current responses for Control, Full-, 
D 16-, D70- and D96-injected oocytes. The control (pRc/ 
CMV plasmid) injected oocytes had no detectable re- 
sponse, while Full, D16 and D47 injeced oocytes had 
very similar SP-induced current responses (Fig. 2, left 
panels and Fig. 3A,C). In contrast to Full SPR, D70 had 
a slight reduction (approximately 30% of peak current) 
in activity (Fig. 2, left panels and Fig. 3A,C). Fig. 3C 
shows the concentration-response curves for SP in Full-, 
D16-, D47- and D70-injected oocytes. SP induced a con- 
centration-dependent increase in current responses, hav- 
ing maximum effects at 30 nM in Full, D16, D47 and 
D70-injected oocytes. D70, on the other hand, had ap- 
proximately 30% smaller maximum current responses. 
The apparent EC,, of SP for Full, D16, D47 and D70 
were identical (4.5 nM). This suggests that wild type and 
mutant SPRs have similar affmity to SP. 
As previously reported, there is a substantial oss of 
activity for D96 with 95% reduction in peak currents 
compared to full-length SP receptor. (Fig. 2, left panels 
and Fig. 3A) [lo]. The D96 results suggest hat the do- 
main between 312 to 337 has a crucial role for receptor 
function, such as G-protein coupling, whereas residues 
from 338 to the C-terminus are not essential for normal 
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receptor function. This finding is consistent with recent 
studies on the comparable regions of adrenergic recep- 
tors [12,13]. 
The SPR mutants were tested in oocytes for their sen- 
sitivity to agonist-induced esensitization. Oocytes were 
Crst stimulated with a maximal dose of SP (30 nM), 
washed for 10 min, and re-stimulated with the same dose 
of SP. The second current responses of Full, D16 and 
D47-injected oocyte were diminished to the same extent 
(Fig. 2, right panels). The magnitudes of the second cur- 
rents were 8.3 f 1.3%, 9.2 + 0.9% and 8.1 + 1.8% of first 
response to SP, respectively (Fig. 3B). Strikingly, the 
D70 mutant exhibited remarkable resistance to desensiti- 
zation, in that the second response was 54 f 6.7% of first 
response (Fig. 2, right panels and Fig. 3B), nearly 7 times 
greater than normally desensitizing SPR responses. 
Because the magnitude of the first current responses 
might affect the magnitude of the second current re- 
sponses, we modulated the level of SPR expression using 
a reduced level of nuclear cDNA injection. Using half the 
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Fig. 2. Representative traces of SP-induced Ca2’-dependent Cl- current 
responses in oocytes injected with SPR or SPR mutants expression 
plasmids. The oocytes were microinjected with pRcKMV plasmid 
(Control) and SPR expression plasmids (Full, D16, D47, D70 and D96; 
100 pg/oocyte) (from top to bottom panels) into nucleus and cultured 
for 48 h as described in section 2. The oocytes were stimulated with SP 
(30 nM, 18 s) (left panels; ‘First’). The oocytes were washed for 10 min 
and re-stimulated with SP (right panels; ‘Second’). Typical data ob- 
tained from 5-22 different oocyte preparations are presented. 
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Fig. 3. SP-induced Ca*+-dependent Cl- current responses in oocytes 
injected with SPR and SPR mutants expression plasmids. (A) Current 
responses in pRc/CMV plasmid (control), Full, D16, D47, D70 and 
D96 cDNA-injected oocytes. Current responses induced by first appli- 
cation of SP (30 nM) are shown as percentage of the first response in 
wild type (Full) of SPR expressed oocytes. The absolute values of 6rst 
response of Full was 910 f 38 (a = 5). (B) Desensitization of SP-in- 
duced current responses in oocytes following Full, D16, D47 and D70 
nuclear microinjection. The results shown are percentage of the second 
current response relative to the tirst current response. The absolute 
values of 6rst response of Full, D16, D47 and D70 were 861 + 92, 
838 + 51, 844 f 66 and 509 + 38 nA (n = 5-9), respectively. (C) SP 
concentration-response curves for current responses in Full, D16, D47 
and D70 cDNA-injected oocytes. The oocytes were stimulated with 
different concentration of SP. Maximum values of the currents were 
plotted. The results shown are mean + S.E. of 3-5 determinations from 
same batch of oocytes. 
amount of cDNA (e.g. 50 pg) of Full, D16 and D47- 
injected oocytes, the first stimulation of SP induced sim- 
ilar reduced magnitudes of current responses, compara- 
ble to that observed with injection of 100 pg of D70 
184 
cDNA into oocyte nuclei. The second current responses 
for Full, D16 and D47-injected oocyte were diminished 
to the same degree as observed with larger magnitudes 
of initial responses (currents were 6.1 + 1.3%, 5.8 f 1.9% 
and 6.3 & 1.8% of first response (n = 5), respectively). 
Thus, it is highly unlikely that the reduced SP-induced 
desensitization in D70 is due to reduced expression. 
The loss of current responses to SP with second appli- 
cation was also reflected in the alterations in latencies of 
initial responses, in that as the peak current response to 
SP diminished, the latency of response became greater. 
The response latency upon second application of SP was 
2.5 s in D70-injected oocytes, whereas the latency for 
second responses was invariably longer for Full (7.7 s), 
D16 (7.8 s) and D47 (8.1 s) (Fig. 2). Since the first current 
responses induced by SP were very small, the D96 mu- 
tant was not examined for the desensitization. 
This identifies a specific region of the C-terminal tail 
of rat SPR from residues 338 to 360 as playing a crucial 
role in agonist-induced esensitization. This domain has 
5 serine and 5 threonine residues, and thus would be a 
candidate for the site of phosphorylation by BARK 1 
and /IARK 2. The stoichiometry of maximum phospho- 
rylation in vitro was calculated to be 9 [5], suggesting 
that a subset of sites may undergo agonist-induced phos- 
phorylation. In addition, this domain, when 
phosphorylated, would be predicted to be the site of 
binding of the regulatory protein,B-arrestin [6,14]. In the 
p,-adrenergic receptor and rhodopsin, the functionally 
equivalent domain lies at a different position in the tail, 
the extreme C-terminus [14]. This may suggest some po- 
tential differences in the mechanisms of BARK//?- 
arrestin pathway in regulation of SPR. 
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